Madrigal Pharmaceuticals Inc (NAS:MDGL)

$ 318.55 -9.64 (-2.94%) Market Cap: 6.95 Bil Enterprise Value: 6.28 Bil PE Ratio: 0 PB Ratio: 8.94 GF Score: 42/100

Q3 2024 Madrigal Pharmaceuticals Inc Earnings Call Transcript
Oct 31, 2024

$259.34 (+20.10%)

Earnings
Q2 2024 Madrigal Pharmaceuticals Inc Earnings Call Transcript
Aug 07, 2024

$234.08 (-12.18%)

Earnings
Q1 2024 Madrigal Pharmaceuticals Inc Earnings Call Transcript
May 07, 2024

$217.96 (-7.48%)

Earnings
Madrigal Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Madrigal Pharmaceuticals Inc at UBS BioPharma Conference Transcript
Nov 08, 2023
Madrigal Pharmaceuticals Inc Phase 3 MAESTRO-NASH Trial Investor Call Transcript
Jun 24, 2023
Madrigal Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Madrigal Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
May 16, 2023
Madrigal Pharmaceuticals Inc to Announce Topline Data from the Phase 3 MAESTRO-NASH Study of Resmetirom Presentation Transcript
Dec 19, 2022
Madrigal Pharmaceuticals Inc EASL Investor Event Call Transcript
Jun 25, 2022
Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Jun 15, 2022
Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 14, 2022
Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference Transcript
May 24, 2022
Q1 2022 Madrigal Pharmaceuticals Inc Earnings Call Transcript
May 09, 2022

$58.04 (-10.14%)

Earnings
Madrigal Pharmaceuticals Inc Call to Discuss MAESTRO-NAFLD-1 Phase 3 Data Transcript
Jan 31, 2022
Madrigal Pharmaceuticals Inc AASLD The Liver Meeting Call Transcript
Nov 16, 2021
Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Madrigal Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference Transcript
May 24, 2021
Madrigal Pharmaceuticals Inc at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020

Madrigal Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 01:40PM GMT

Release Date Price: $106.81 (-0.37%)

Transcript

Andrea R. Tan

Goldman Sachs Group, Inc., Research Division - Research Analyst

Good morning, everyone. Thanks for joining us on the last day of our conference. I'm Andrea Tan, biotech analyst at Goldman Sachs. And I'm pleased to have with us the team from Madrigal, Paul Friedman, CEO; Becky Taub, CMO and President of R&D; Remy Sukhija, CCO; and newly appointed CFO, Alex Howarth. With that, maybe, Paul, I'll start with you and turn it over for opening remarks.

Paul A. Friedman

Madrigal Pharmaceuticals, Inc. - Chairman & CEO

Sure. Andrea, we're pleased to be here. Appreciate your recent positive coverage of Madrigal. For those of you who may not be familiar with Madrigal, before beginning the Q&A, we have a few high-level slides to share as a brief introduction to our company and resmetirom, our liver-directed thyroid receptor beta agonist.

Can we see Slide 2, please? Okay. So this is our fine print regarding forward-looking statements, and you can peruse it at your leisure.

Next slide. To begin, Madrigal has an experienced

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.